Compare OXBR & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXBR | PFSA |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0M | 8.9M |
| IPO Year | 2014 | N/A |
| Metric | OXBR | PFSA |
|---|---|---|
| Price | $1.08 | $0.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 14.9K | ★ 14.6M |
| Earning Date | 03-25-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,423,000.00 | N/A |
| Revenue This Year | $497.99 | N/A |
| Revenue Next Year | $42.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 122.22 |
| 52 Week Low | $0.99 | $0.05 |
| 52 Week High | $5.81 | $12.76 |
| Indicator | OXBR | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 31.73 | 31.07 |
| Support Level | $1.01 | $0.08 |
| Resistance Level | $1.13 | $0.10 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 6.67 | 2.28 |
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.